NCT07813728 Internet-Delivered Acceptance and Commitment Therapy (iACT) for Youth With PTSD and Chronic Pain
| NCT ID | NCT07813728 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Skane University Hospital |
| Condition | Chronic Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-09-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 10 participants in total. It began in 2026-09-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary aim of this study is to investigate the effect of Internet-delivered Acceptance and commitment therapy for youth with PTSD and comorbid chronic pain. A pilot study (no randomization; N=5-10) will be conducted to test the intervention and assessment procedures. The participants will go through an active internet-based ACT treatment focused on education about PTSD, value-based exposure for the traumatic memory and avoided situations, and behavior change through exercises targeting the processes mindfulness, cognitive defusion and acceptance. The treatment is delivered on a safe internet platform. Participants have planned telephone contact with their assigned psychologist 3 times during the program and can also contact their psychologist via a message system in the platform and expect answer within 48 hours.
Eligibility Criteria
Inclusion criteria * a CAPS of ≥25 and a diagnosis of PTSD * subjected to single traumatic events * aged 15-24 years * had symptoms of chronic pain that interfered significantly with everyday life * were fully examined medically and had received medical treatment if indicated * were able to be an active part of the rehabilitation process, regain functioning in different life areas and participate in treatment interventions for approximately 5 hours every week * stable dose of medication * able to read and write in Swedish * had access to a smart phone or computer with internet access Exclusion criteria * repeated and extensive traumatic events * had other acute or severe psychiatric disorders or symptoms that warranted designation as the primary disorder (ADHD, autism spectrum disorder, untreated bipolar disorder, OCD, psychotic symptoms, severe depression, ) * were actively abusing analgesic medications (including narcotics), alcohol or other drugs * had great difficulty to harbour and handle strong emotions that could lead to self-harming behavior * had health risks due to medical reasons * had social or economic difficulties or lack of social support that hindered behavior change * current severe suicidal ideation that warranted immediate intervention
Contact & Investigator
Sophia Åkerblom, phd
PRINCIPAL INVESTIGATOR
Skane University Hospital
Frequently Asked Questions
Who can join the NCT07813728 clinical trial?
This trial is open to participants of all sexes, aged 15 Years or older, up to 24 Years, studying Chronic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07813728 currently recruiting?
Yes, NCT07813728 is actively recruiting participants. Contact the research team at sophia.akerblom@skane.se for enrollment information.
Where is the NCT07813728 trial being conducted?
This trial is being conducted at Lund, Sweden.
Who is sponsoring the NCT07813728 clinical trial?
NCT07813728 is sponsored by Skane University Hospital. The principal investigator is Sophia Åkerblom, phd at Skane University Hospital. The trial plans to enroll 10 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.